DOC Stock Analysis: Healthpeak Properties | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 13.817m USD | 12M Return: 8.9% | US42250P1030 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 116M
Qual. Beats: 0
Rev. Trend: 94.8%
Qual. Beats: 4
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Healthpeak Properties, Inc. (NYSE: DOC) is a large-cap real estate investment trust (REIT) and S&P 500 constituent that owns, operates, and develops real estate focused on healthcare discovery and delivery. The company is headquartered in Denver, Colorado, was incorporated in Maryland in 1985, and has been publicly traded since 1987.
As a REIT, Healthpeak is generally required to distribute the majority of its taxable income to shareholders as dividends in exchange for pass-through tax treatment. Within the GICS classification system, the company sits in the Health Care REITs sub-industry, a sector that invests in property types such as medical office buildings, outpatient facilities, senior housing, and life science and research campuses.
- Medical outpatient and lab occupancy drives same-store NOI growth
- Interest rate volatility pressures cap rates and borrowing costs
- Capital recycling funds acquisitions of higher-yielding outpatient medical assets
| Net Income: 253.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -4.92 > 1.0 |
| NWC/Revenue: 38.57% < 20% (prev -18.62%; Δ 57.19% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.23b > Net Income 253.7m |
| Net Debt (8.98b) to EBITDA (1.78b): 5.04 < 3 |
| Current Ratio: 2.52 > 1.5 & < 3 |
| Outstanding Shares: last quarter (689.9m) vs 12m ago -1.04% < -2% |
| Gross Margin: 2.53% > 18% (prev 60.42%; Δ -57.88% > 0.5%) |
| Asset Turnover: 14.22% > 50% (prev 14.11%; Δ 0.11% > 0%) |
| Interest Coverage Ratio: 2.03 > 6 (EBIT TTM 685.2m / Interest Expense TTM 337.0m) |
| A: 0.05 (Total Current Assets 1.89b - Total Current Liabilities 750.4m) / Total Assets 21.7b |
| B: -0.27 (Retained Earnings -5.95b / Total Assets 21.7b) |
| C: 0.03 (EBIT TTM 685.2m / Avg Total Assets 20.7b) |
| D: 0.64 (Book Value of Equity 7.84b / Total Liabilities 12.2b) |
| Altman-Z'' = 0.35 = B |
| DSRI: 0.32 (Receivables 261.4m/785.3m, Revenue 2.95b/2.80b) |
| GMI: 23.85 (GM 60.42% / 2.53%) |
| AQI: 0.96 (AQ_t 0.89 / AQ_t-1 0.93) |
| SGI: 1.06 (Revenue 2.95b / 2.80b) |
| TATA: -0.05 (NI 253.7m - CFO 1.23b) / TA 21.7b) |
| Beneish M = 17.13 (Cap -4..+1) = D |
As of October 12, 2026, the stock is trading at USD 18.80 with a total of 5,694,674 shares traded. Over the past week, the price has changed by -3.54%, over one month by -7.33%, over three months by -11.57% and over the past year by +8.88%.
Current recommended Stop Loss: 18.20 (which is 3.2% or 1.5 ATR below the current price).
Healthpeak Properties has received a consensus analysts rating of 3.59. Therefore, it is recommended to hold DOC.
- StrongBuy: 5
- Buy: 3
- Hold: 14
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 23 | 22.1% |
P/E Trailing = 55.6857
P/E Forward = 169.4915
P/S = 4.6842
P/B = 1.8001
P/EG = 4.0809
Revenue TTM = 2.95b USD
EBIT TTM = 685.2m USD
EBITDA TTM = 1.78b USD
Long Term Debt = 8.54b USD (from longTermDebt, last quarter)
Short Term Debt = 750.4m USD (from shortTermDebt, last quarter)
Debt = 10.6b USD (from shortLongTermDebtTotal, last quarter) + Leases 288.2m
Net Debt = 8.98b USD (calculated: Debt 10.6b - CCE 1.63b)
Enterprise Value = 22.8b USD (13.8b + Debt 10.6b - CCE 1.63b)
Interest Coverage Ratio = 2.03 (Ebit TTM 685.2m / Interest Expense TTM 337.0m)
EV/FCF = 76.97x (Enterprise Value 22.8b / FCF TTM 296.2m)
FCF Yield = 1.30% (FCF TTM 296.2m / Enterprise Value 22.8b)
FCF Margin = 10.04% (FCF TTM 296.2m / Revenue TTM 2.95b)
Net Margin = 8.60% (Net Income TTM 253.7m / Revenue TTM 2.95b)
Gross Margin = 2.53% ((Revenue TTM 2.95b - Cost of Revenue TTM 2.88b) / Revenue TTM)
Gross Margin QoQ = 56.83% (prev -19.97%)
Tobins Q-Ratio = 1.05 (Enterprise Value 22.8b / Total Assets 21.7b)
Interest Expense / Debt = 3.18% (Interest Expense 337.0m / Debt 10.6b)
Taxrate = 1.32% (3.67m / 278.5m)
NOPAT = 676.2m (EBIT 685.2m * (1 - 1.32%))
Current Ratio = 2.52 (Total Current Assets 1.89b / Total Current Liabilities 750.4m)
Debt / Equity = 1.35 (Debt 10.6b / totalStockholderEquity, last quarter 7.84b)
Debt / EBITDA = 5.04 (Net Debt 8.98b / EBITDA 1.78b)
Debt / FCF = 30.32 (Net Debt 8.98b / FCF TTM 296.2m)
Total Stockholder Equity = 7.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.22% (Net Income 253.7m / Total Assets 21.7b)
RoE = 3.30% (Net Income TTM 253.7m / Total Stockholder Equity 7.69b)
RoCE = 4.22% (EBIT 685.2m / Capital Employed (Equity 7.69b + L.T.Debt 8.54b))
RoIC = 3.14% (NOPAT 676.2m / Invested Capital 21.5b)
WACC = 5.05% (E(13.8b)/V(24.4b) * Re(6.52%) + D(10.6b)/V(24.4b) * Rd(3.18%) * (1-Tc(0.01)))
Discount Rate = 6.52% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 42.49 | Cagr: 6.31%
[DCF] Terminal Value 73.10% ; FCFF base≈675.6m ; Y1≈592.4m ; Y5≈478.7m
[DCF] Fair Price = N/A (negative equity: EV 7.68b - Net Debt 8.98b = -1.30b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.16 | # QB: 0
Revenue Correlation: 94.83 | Revenue CAGR: 12.70% | SUE: 1.85 | # QB: 4
EPS current Quarter (2026-09-30): EPS=0.03 | Chg30d=N/A | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=0.09 | Chg30d=N/A | Revisions=-25% | GrowthEPS=+130.8% | GrowthRev=+6.6%
EPS next Year (2027-12-31): EPS=0.14 | Chg30d=+193.33% | Revisions=-25% | GrowthEPS=+55.6% | GrowthRev=+7.1%
[Analyst] Revisions Ratio: -40% (up=0, down=2)